Team

Executive Committee

	IBA team

Executive Committee

Dr. Lothar Germeroth Chief Executive Officer Lothar Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel prize laureate Prof. Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt. He started his professional carreer as group leader in a diagnostic company where he was responsible for the development of PCR-based HLA-dignostics and the quality control system of the company. Subsequently he served for eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos biotechnology AG in Switzerland where he has closed several multimillion dollar deals with pharma industry. In April 2002, he joined IBA GmbH as CEO.

Dr. Thomas Schmidt Chief Operating Officer Thomas Schmidt studied biology in Munich and completed his studies with a Diplom thesis on antibody engineering in the laboratory of Prof. Plueckthun. After that he entered the department of Nobel prize laureate Prof. Michel at the Max-Planck Institute of Biophysics in Frankfurt, where he worked on his PhD thesis in the laboratory of Prof. Skerra. There he focused his research activities on molecular recognition and invented, together with Prof. Skerra, the Strep-tag technology for detection, purification, and assay of recombinant proteins. In July 1994, he was appointed by IBA, where he further developed this technology, transformed it into successful products, and managed their commercialization.

Dr. Joachim Bertram Chief Scientific Officer Joachim Bertram received his Ph.D. in microbiology in the department of Prof. Gottschalk at the University of Goettingen. Then he moved to the department of hematology and oncology headed by Prof. Hiddemann where he has held a number of positions of increasing seniority in the biomedical profession. He conducted scientific and applied research on the use of antisense oligonucleotides and ribozymes in the field of proliferative diseases. In addition he focussed on mechanisms of drug resistance development and the use of nucleic acid based compounds for growth factor mimicry. In 1998, Joachim Bertram finished his "habilitation" in the medical faculty. He joined IBA GmbH in January 2000 and became CEO of IBA Biologics in 2001.

Dr. Herbert Stadler Head of the Advisory Board Over the last two decades, Herbert Stadler has built a track record as one of Germany's most active biotech entrepreneurs. He has founded or co founded several companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Herbert Stadler is a neurochemist by training. He obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of DeveloGen AG and IBA GmbH.

Product Management

Dipl. Biol. Bettina Renker, MSc, Product Manager "Transfection and Nucleic acids"
Dr. Gisela Mäck, Product Manager "Cell TAGnologies"
Dr. Isabel Schuchardt, Product Manager "Cloning/Expression/Purification"

Recombinant Proteins

Dr. Uwe D. Carl

Nucleic Acids

Dr. Kai Franke



General contact information
Phone +49 (0) 551 50672-0
Fax +49 (0) 551 50672-181
E-mail info@iba-go.com